India is grappling with a significant rise in counterfeit high-value medications, including cancer therapies and weight-loss injections, which poses serious risks to patient safety. These counterfeit operations are not mere quality lapses but organized criminal activities that exploit weaknesses in the healthcare supply chain.
Recent investigations reveal that counterfeiters are capitalizing on gaps in hospital waste disposal and supply chains. For instance, authentic vials of Merck's Keytruda have been refilled with ineffective substances and resold, jeopardizing cancer patients' treatment outcomes. Similar counterfeit schemes are emerging in the obesity and diabetes sectors, where fake versions of popular therapies have been discovered, raising serious safety concerns due to improper storage and dubious sourcing methods.
Despite the integration of AI tools in supply chain management, such as predictive analytics and real-time visibility, the pharmaceutical sector faces critical vulnerabilities. Weak packaging controls, ineffective serialization, and low public awareness contribute to the issue, making counterfeit products enticing to consumers due to steep discounts and informal sales channels.
While AI technology can enhance detection and monitoring of counterfeit drugs, it is not a standalone solution. Comprehensive measures, including stricter enforcement protocols, vigilant procurement practices, and patient education, are essential to combat this crisis. The responsibility lies with pharma companies, healthcare providers, and patients to ensure safety throughout the drug lifecycle, emphasizing the importance of verified sources and awareness campaigns to protect public health.